Characterisation of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-2018

Objectives Third-generation cephalosporin-resistant Escherichia coli from community-acquired urinary tract infections (UTI) have been increasingly reported worldwide. In this study we sought to determine and characterise the mechanisms of cefotaxime-resistance (CTX-R) employed by urinary E. coli obtained from primary care over a 12-month period, in Bristol and surrounding counties in the South West of England. Methods Cephalexin resistant (Ceph-R) E. coli isolates were identified directly from general practice (GP) referred urine samples using disc susceptibility testing as per standard diagnostic procedures. CTX-R was determined by subsequent plating onto MIC breakpoint plates. β-Lactamase genes were detected by PCR. Whole Genome Sequencing (WGS) was performed on 225 urinary isolates and analyses were performed using the Centre for Genomic Epidemiology platform. Patient information provided by the referring GPs was reviewed. Results During the study period, Ceph-R E. coli (n=900) were obtained directly from urines from 146 GPs. Seventy-percent (626/900) of isolates were CTX-R. WGS of 225 non-duplicate isolates identified that the most common mechanism of CTX-R was blaCTX-M carriage (185/225; 82.2%), predominantly blaCTX-M-15 (114/185; 61.6%), followed by carriage of plasmid mediated AmpCs (pAmpCs) (17/225; 7.6%), ESBL blaSHV variants (6/225; 2.7%), AmpC hyperproduction (13/225; 5.8%), or a combination of both blaCTX-M and pAmpC carriage (4/225; 1.8%). Forty-four sequence types (STs) were identified with ST131 representing 101/225 (45.0%) of sequenced isolates, within which the blaCTX-M-15-positive clade C2 was dominant (54/101; 53.5%). Ciprofloxacin-resistance (CIP-R) was observed in 128/225 (56.9%) of sequenced CTX-R isolates – predominantly associated with fluoroquinolone-resistant clones ST131 and ST1193. Conclusions Most Ceph-R urinary E. colis were CTX-R, predominantly caused by blaCTX-M carriage. There was a clear correlation between CTX-R and CIP-R, largely attributable to the dominance of the high-risk pandemic clones, ST131 and ST1193 in this study. This localised epidemiological data provides greater resolution than regional data and can be valuable for informing treatment choices in the primary care setting.

[1]  A. Birgy,et al.  Independent Host Factors and Bacterial Genetic Determinants of the Emergence and Dominance of Escherichia coli Sequence Type 131 CTX-M-27 in a Community Pediatric Cohort Study , 2019, Antimicrobial Agents and Chemotherapy.

[2]  C. Torres,et al.  Adherent/invasive Escherichia coli (AIEC) isolates from asymptomatic people: new E. coli ST131 O25:H4/H30-Rx virotypes , 2018, Annals of Clinical Microbiology and Antimicrobials.

[3]  P. Aylin,et al.  Exploring the relationship between primary care antibiotic prescribing for urinary tract infections, Escherichia coli bacteraemia incidence and antimicrobial resistance: an ecological study. , 2018, International journal of antimicrobial agents.

[4]  J. Schrenzel,et al.  Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe , 2018, The Journal of antimicrobial chemotherapy.

[5]  D. Lecky,et al.  CTX-M ESBL-producing Enterobacteriaceae: estimated prevalence in adults in England in 2014 , 2018, The Journal of antimicrobial chemotherapy.

[6]  R. Lyons,et al.  Risk factors for Escherichia coli bacteraemia: a population-based case-control study , 2017, The Lancet.

[7]  F. Hansen,et al.  Prevalence of antimicrobial resistant Escherichia coli from patients with suspected urinary tract infection in primary care, Denmark , 2017, BMC Infectious Diseases.

[8]  P. Hawkey,et al.  Global epidemiology of CTX-M &bgr;-lactamases: temporal and geographical shifts in genotype , 2017, The Journal of antimicrobial chemotherapy.

[9]  J. Pitout,et al.  Escherichia coli ST131: a multidrug-resistant clone primed for global domination , 2017, F1000Research.

[10]  G. Peirano,et al.  Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene , 2016, Emerging infectious diseases.

[11]  N. Woodford,et al.  Clonal expansion of Escherichia coli ST38 carrying a chromosomally integrated OXA-48 carbapenemase gene. , 2016, Journal of medical microbiology.

[12]  Jianzhong Shen,et al.  Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. , 2015, The Lancet. Infectious diseases.

[13]  J. Wain,et al.  Rapid Identification of Major Escherichia coli Sequence Types Causing Urinary Tract and Bloodstream Infections , 2014, Journal of Clinical Microbiology.

[14]  Torsten Seemann,et al.  Prokka: rapid prokaryotic genome annotation , 2014, Bioinform..

[15]  D. Mevius,et al.  Chromosomal location of blaCTX-M genes in clinical isolates of Escherichia coli from Germany, The Netherlands and the UK. , 2014, International journal of antimicrobial agents.

[16]  Ole Lund,et al.  In Silico Detection and Typing of Plasmids using PlasmidFinder and Plasmid Multilocus Sequence Typing , 2014, Antimicrobial Agents and Chemotherapy.

[17]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[18]  Nicola K. Petty,et al.  Global dissemination of a multidrug resistant Escherichia coli clone , 2014, Proceedings of the National Academy of Sciences.

[19]  E. Denamur,et al.  Virulence Patterns in a Murine Sepsis Model of ST131 Escherichia coli Clinical Isolates Belonging to Serotypes O25b:H4 and O16:H5 Are Associated to Specific Virotypes , 2014, PloS one.

[20]  L. Price,et al.  Molecular Epidemiology of Escherichia coli Sequence Type 131 and Its H30 and H30-Rx Subclones among Extended-Spectrum-β-Lactamase-Positive and -Negative E. coli Clinical Isolates from the Chicago Region, 2007 to 2010 , 2013, Antimicrobial Agents and Chemotherapy.

[21]  J. Campos,et al.  Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain. , 2013, The Journal of antimicrobial chemotherapy.

[22]  S. Rasmussen,et al.  Identification of acquired antimicrobial resistance genes , 2012, The Journal of antimicrobial chemotherapy.

[23]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[24]  P. Hawkey,et al.  High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UK. , 2012, The Journal of antimicrobial chemotherapy.

[25]  R. Zbinden,et al.  Detection of AmpC Beta-Lactamase in Escherichia coli: Comparison of Three Phenotypic Confirmation Assays and Genetic Analysis , 2011, Journal of Clinical Microbiology.

[26]  N. Perna,et al.  progressiveMauve: Multiple Genome Alignment with Gene Gain, Loss and Rearrangement , 2010, PloS one.

[27]  D. Mangin Urinary tract infection in primary care , 2010, BMJ : British Medical Journal.

[28]  A. Marchese,et al.  The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. , 2009, International journal of antimicrobial agents.

[29]  E. Denamur,et al.  The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. , 2008, The Journal of antimicrobial chemotherapy.

[30]  F. Baquero,et al.  Dissemination of Clonally Related Escherichia coli Strains Expressing Extended-Spectrum β-Lactamase CTX-M-15 , 2008, Emerging infectious diseases.

[31]  J. Blanco,et al.  Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. , 2007, The Journal of antimicrobial chemotherapy.

[32]  T. Walsh,et al.  Occurrence and current frequency of CTX-M-type beta-lactamases from a regional hospital in the South West of England. , 2007, The Journal of antimicrobial chemotherapy.

[33]  F. Baquero,et al.  Antibiotic Coresistance in Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae and In Vitro Activity of Tigecycline , 2006, Antimicrobial Agents and Chemotherapy.

[34]  Daniel Falush,et al.  Sex and virulence in Escherichia coli: an evolutionary perspective , 2006, Molecular microbiology.

[35]  L. Nicolle Epidemiology of urinary tract infections , 2002 .

[36]  Betsy Foxman,et al.  Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. , 2002, The American journal of medicine.

[37]  N. Caroff,et al.  Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC. , 2000, The Journal of antimicrobial chemotherapy.

[38]  N. Woodford,et al.  Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. , 2006, The Journal of antimicrobial chemotherapy.

[39]  G. Kahlmeter An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. , 2003, The Journal of antimicrobial chemotherapy.